54
Participants
Start Date
June 19, 2020
Primary Completion Date
January 19, 2024
Study Completion Date
May 23, 2024
BNT411
intravenous
Atezolizumab
intravenous
Carboplatin
intravenous
Etoposide
intravenous
University Medical Center Hamburg-Eppendorf - (Recruiting only for part 1B and part 2), Hamburg
Clinica Universidad de Navarra, Madrid
START Madrid - CIOCC. Grupo Hospital de Madrid (HM) - Centro Integral Oncologico Clara Campal (CIOCC), Madrid
Prisma Health-Upstate Cancer Institute, Greenville
Hospital Universitario La Fe de Valencia, Valencia
Universitaetsklinikum Koeln - (Recruiting only for part 1B and part 2), Cologne
Universitaetsmedizin der Johannes Gutenberg Universitat Mainz KoeR - (Recruiting only for part 1B and part 2), Mainz
Northwestern Medical Faculty Foundation, Chicago
Cedars-Sinai Medical Center, Los Angeles
Hospital Universitari Vall d'Hebron, Barcelona
Edinburgh Cancer Research Centre, Edinburgh
Sarah Cannon Research Institute, London
Lead Sponsor
BioNTech SE
INDUSTRY